Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Santhera Pharmaceuticals Holding AG's Revenue for the
six
months ended in Dec. 2025 was $66.72 Mil. Santhera Pharmaceuticals Holding AG's average Accounts Receivable for the
six
months ended in Dec. 2025 was $12.35 Mil.
Hence, Santhera Pharmaceuticals Holding AG's Receivables Turnover for the
six
months ended in Dec. 2025 was 5.40.
Santhera Pharmaceuticals Holding AG (OTCPK:SPHDF) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Santhera Pharmaceuticals Holding AG Receivables Turnover Related Terms
Santhera Pharmaceuticals Holding AG Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santhera Pharmaceuticals Holding AG Receivables Turnover Chart
SPHDF vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Santhera Pharmaceuticals Holding AG Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Santhera Pharmaceuticals Holding AG's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santhera Pharmaceuticals Holding AG (SPHDF) has a Receivables Turnover of 5.40 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Santhera Pharmaceuticals Holding AG and its competitors. According to the industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #256 out of 841 companies in the Biotechnology industry, placing it in the top 30.4%.
Is Santhera Pharmaceuticals Holding AG's Receivables Turnover too high?
Santhera Pharmaceuticals Holding AG's current Receivables Turnover is 5.40. The Biotechnology industry median Receivables Turnover is 5.29. Santhera Pharmaceuticals Holding AG's value of 5.40 is 2.1% above this industry median. Based on the distribution chart, Santhera Pharmaceuticals Holding AG ranks #256 out of 841 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Santhera Pharmaceuticals Holding AG has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Santhera Pharmaceuticals Holding AG's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #256 out of 841 companies for Receivables Turnover. This puts Santhera Pharmaceuticals Holding AG in the upper half of its industry. The industry median Receivables Turnover is 5.29. Santhera Pharmaceuticals Holding AG's value of 5.40 is 2.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Santhera Pharmaceuticals Holding AG's current Receivables Turnover of 5.40 is 2.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Santhera Pharmaceuticals Holding AG and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Santhera Pharmaceuticals Holding AG's current Receivables Turnover is 5.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santhera Pharmaceuticals Holding AG stock overvalued right now?
Santhera Pharmaceuticals Holding AG (SPHDF) has a current Receivables Turnover of 5.40. The stock's GF Value™ is $35.65, compared to a current price of $23.25 — trading 34.8% below its estimated fair value. The current Receivables Turnover is 5.40 and 2.1% above the Biotechnology industry median of 5.29. Santhera Pharmaceuticals Holding AG's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Santhera Pharmaceuticals Holding AG (SPHDF), the current Receivables Turnover is 5.40 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Santhera Pharmaceuticals Holding AG (SPHDF) Overvalued in 2026?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG stock appears to be undervalued.
The current stock price of $23.25 is trading 34.8% below its estimated GF Value™ of $35.65.
Key valuation signals for SPHDF:
Receivables Turnover: 5.40
GF Value™: $35.65 vs. price of $23.25 (34.8% below fair value)
Industry Position: 2.1% above the Biotechnology median (#256 of 841)
No single metric tells the full story. See the SPHDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Santhera Pharmaceuticals Holding AG Business Description
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company committed to developing and commercializing medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. It is focused on the development of treatments for pulmonary and neuromuscular diseases that currently lack treatment options. The company is currently engaged in the rollout of its AGAMREE (vamorolone) medicine for the treatment of Duchenne muscular dystrophy (DMD) globally. Santhera has one operating segment, namely the development and commercialization of products for the treatment of neuromuscular diseases. Geographically, the company generates maximum revenue from Europe, and the rest from Asia and North America.
39GF Score
Get the complete analysis for SPHDF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPHDF has been successfully added to your 
